Stay updated with breaking news from Interventional Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Publication of MERIT Study Follows FDA Market Authorization of Apollo ESGAUSTIN, TX / ACCESSWIRE / July 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive
AUSTIN, TX / ACCESSWIRE / May 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced
Trial Results Demonstrate ESG Procedure Offers Significant and Durable Weight Loss, with Improvements in Obesity-Related Health ConditionsMERIT-Trial met its primary endpoints for safety and efficacy,
Revenue expected between $16.0 million and $16.4 millionThird consecutive quarter of double-digit revenue growth; endoscopic suturing up over 30%Submitted a De Novo 510(k) Classification Request to FDA
Apollo Endosurgery, Inc. Reports Record Endoscopy Revenue in Second Quarter, Raises Full-Year Outlook Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET ACCESSWIRE 04 Aug 2021, 06:05 GMT+10 AUSTIN, TX / ACCESSWIRE / August 3, 2021 / Apollo Endosurgery, Inc. ('Apollo') (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2021. Highlights Achieved total revenue of $16.6 million, an increase of 194% compared to the second quarter of 2020, and a ne...